-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Theravance Biopharma, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2024 to Q1 2025.
- Theravance Biopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was -$1.85M, a 261% decline year-over-year.
- Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$7.57M, a 336% decline from 2023.
- Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $3.21M.
- Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2017 was $0.000.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)